Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Background: People get malaria when they are bitten by an infected mosquito. Malaria can be serious and sometimes deadly. Although there are medicines to treat malaria, there is no vaccine that fully prevents infection. Researchers want to test if an experimental drug can help. Objective: To test a drug called CIS43LS that could prevent malaria infection. Eligibility: Healthy people ages 18-50 who have never been infected with malaria Design: Participants will be screened with a physical exam, blood tests, and medical history. Some participants will get pregnancy tests. Most participants will get CIS43LS. They will get the drug infused into a vein in their arm or injected into the fat under the skin. They will be monitored for side effects for up to 4 hours after they get the drug. Participants will be given a thermometer to check their temperature every day for 7 days. They will also be given a device to measure any redness, swelling, or bruising at the injection site. Participants will have up to 12 follow-up visits. These will include blood tests. Most participants will take part in a Controlled Human Malaria Challenge (CHMI). During the CHMI, mosquitoes carrying the malaria parasite will bite participants in a controlled setting. The participants will then have clinic visits every day for up to 12 days starting 7 days after the CHMI. They will be treated right away with antimalarial medication if the test shows positive for malaria. If participants continue to test negative for malaria, they will have 2 more visits over the next 6 days for blood tests. Then 28 days after the CHMI they will get treated with antimalarial medication for 3 days. The study will last 2-6 months depending on participants study group....
Description: 5 mg/kg IV of CIS43LS will be administered to healthy, malaria-naive adults.
Measure: To evaluate the safety and tolerability of CIS43LS Time: Through 24 weeks after product administrationDescription: 20 mg/kg IV of CIS43LS will be administered to healthy, malaria-naive adults.
Measure: To evaluate the safety and tolerability of CIS43LS Time: Through 24 weeks after product administrationDescription: 40 mg/kg IV of CIS43LS will be administered to healthy, malaria-naive adults.
Measure: To evaluate the safety and tolerability of CIS43LS Time: Through 24 weeks after product administrationDescription: 5mg/kg SC of CIS43LS will be administered to healthy, malaria-naive adults.
Measure: To evaluate the safety and tolerability of CIS43LS Time: Through 24 weeks after product administrationDescription: The pharmocokinetics of CIS43LS administered at each dose level will be evaluated.
Measure: To evaluate the pharmacokinetics of CIS43LS at each dose level Time: Throughout the studyDescription: To determine if the administration of CIS43LS confers protection against plasmodium falciparum following CHMI.
Measure: To determine if CIS43LS confers protection Time: Following CHMIAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports